3413 results for «2025»
3413 results
How to manage treatment dilemmas in STEMI patients with multivessel disease?
20 May 2025 – From EuroPCR 2025
Managing STEMI patients with multivessel disease is a complex challenge evolving rapidly thanks to new clinical evidence. Angela Mcinerney, Natalia Pinilla, and Matthias Götberg explore how findings from the COMPLETE trial and its intracoronary imaging substudy are reshaping treatment strategies.
Their discussion highlights the role of intracoronary...
What is the latest in DCB practice?
21 May 2025 – From EuroPCR 2025
Robert Byrne and Bruno Scheller explore the current role of drug-coated balloon (DCB) angioplasty nearly two decades after its initial clinical use. This discussion covers when and how to apply DCB angioplasty effectively in everyday practice, focusing on lesion preparation for de novo coronary disease and...
What are the essentials of the provisional strategy for non-left main true bifurcation lesions?
21 May 2025 – From EuroPCR 2025
Giuseppe Di Gioia and Jens Flensted Lassen explore the essentials of the provisional stenting strategy for non-left main true bifurcation lesions. This stepwise approach offers simplicity while preserving flexibility: start with one stent in the main vessel, and keep the option open for a second if...
Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis
21 May 2025 – From EuroPCR 2025
Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.
Patients with under-expanded valves faced higher risks...
Vulnerable plaque PCI after PREVENT
22 May 2025 – From EuroPCR 2025
This interview with Michael Haude and Thomas Cuisset explores findings from the PREVENT trial, which included over 1,600 patients with vulnerable, physiologically non-significant plaques identified by IVUS.
Patients were randomised to optimal medical therapy (OMT) alone or OMT plus preventive PCI. While the composite endpoint favoured the PCI...
How will EARLY-TAVI and NOTION-3 impact TAVI practice?
21 May 2025 – From EuroPCR 2025
When is the right time to perform TAVI—and how should coexisting coronary artery disease be managed? In this interview, Liesbeth Rosseel, Davide Capodanno, and Michael Joner tackle these two timely questions. They share key takeaways from the EARLY-TAVI trial, which demonstrated reduced rehospitalisation with early intervention...
From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system
16 Nov 2025 – From PCR London Valves 2025
Rebecca Hahn, Varius Dannenberg and Matti Adam discuss the updated ESC/EACTS guidelines for tricuspid regurgitation, which upgrade transcatheter tricuspid interventions to a IIa recommendation. Evidence from the TRILUMINATE and TRISCEND II trials shows improved quality of life and reduced heart failure hospitalisations, especially in patients with...
From clinical benefits to cost effectiveness: impact of early intervention in asymptomatic severe AS
16 Nov 2025 – From PCR London Valves 2025
Francesco Saia discusses the clinical benefits of early intervention in asymptomatic severe aortic stenosis with Philippe Généreux and Tiffany Patterson. EARLY TAVR trial and supporting studies showed a reduction in death, stroke, and heart failure compared with surveillance. Economic modelling shows early intervention is cost-effective and...
In what situation is emergency transcatheter valve intervention a valid alternative to surgery?
16 Nov 2025 – From PCR London Valves 2025
Azeem Latib and Giuseppe Tarantini discuss how transcatheter therapies are increasingly used to treat critically ill patients with severe valvular disease and cardiogenic shock—patients once considered untreatable. They highlight cases ranging from severe AS with ACS to acute papillary muscle rupture and acute severe regurgitation, showing...
TAVI for aortic regurgitation in high surgical risk: outcomes in 700 patients from ALIGN-AR
16 Nov 2025 – From PCR London Valves 2025
Christopher Allen and Raj Makkar sit down to review the ALIGN-AR trial and its implications for treating native aortic regurgitation.
ALIGN-AR was a pivotal, single-arm, multicenter investigational study designed to evaluate a dedicated transcatheter solution in patients with moderate-to-severe native AR who were considered high risk for...
How to successfully approach calcified bifurcation lesions?
20 May 2025 – From EuroPCR 2025
Calcified bifurcation lesions remain one of the toughest challenges in interventional cardiology, combining two high-risk features into one complex scenario.
In this discussion, Dejan Milasinovic, Miroslaw Ferenc, and Mohamed Abdel Wahab explain why this subset deserves dedicated attention. They highlight the critical role of intra-coronary imaging to...
How to successfully approach CTO interventions: a step-by-step approach
22 Oct 2025 – From EuroPCR 2025
Elliot Smith, Thomas Hovasse and Roberto Garbo discuss a comprehensive, step-by-step approach to CTO interventions, providing structured guidance on navigating CTOs in a safe and effective way.
The discussion begins with angiographic assessment, emphasising the importance of identifying key anatomical features upfront. Based on this evaluation, operators determine...
One-year results from the ADALA trial
16 Nov 2025 – From PCR London Valves 2025
Left atrial appendage (LAA) closure is a new focus at this year’s PCR London Valves Course, and, in this interview, Xavier Freixa and Christopher Allen discuss the ADALA trial and its impact on post-occlusion management.
The study compared three months of low-dose DOAC with three months of...
TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation
16 Nov 2025 – From PCR London Valves 2025
Georg Nickenig and Christopher Allen discuss transcatheter replacement for the tricuspid valve and a dedicated transfemoral device in this interview, focusing on the TARGET study.
TARGET set out to answer two questions: can tricuspid regurgitation (TR) be reduced to mild or zero, and what are the safety...
PARTNER 3 — 7-year follow-up: what it means for low-risk patients
16 Nov 2025 – From PCR London Valves 2025
Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.
They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...
Early treatment of severe aortic stenosis: do we need to wait?
20 May 2025 – From EuroPCR 2025
Rahul Sharma and Darren Walters share their perspectives on shifting treatment strategies for aortic stenosis (AS), with a focus on early intervention.
Their conversation draws on the EARLY TAVR trial, which compared transcatheter aortic valve replacement (TAVR) to clinical surveillance in patients with severe, asymptomatic AS at low surgical...
Five-year outcomes following early experience with transapical TMVR
16 Nov 2025 – From PCR London Valves 2025
In this discussion, Christopher Allen and Michael Reardon review the five-year results of an early transapical TMVR system implanted in very high-risk, inoperable patients.
The device showed sustained elimination of mitral regurgitation, with over 80% of patients maintaining trace or no MR at five years and no...
PCR Tricuspid Focus Group - referral meeting in Utrecht
23 Nov 2023
Join your peers for this meeting on 22 January 2025 in Utrecht, Netherlands!
PCR Tricuspid Focus Group - referral meeting in Milan
10 Jul 2023
Join your peers for this meeting on 13-14 January 2025 in Milan, Italy!
PCR Tricuspid Focus Group - referral meeting in London
21 Mar 2023
Join your peers for this meeting on 10 January 2025 in London, United Kingdom!
